- 专利标题： MONOCLONAL ANTIBODIES SPECIFIC FOR FIBROBLAST GROWTH FACTOR RECEPTOR 4 (FGFR4) AND METHODS OF THEIR USE
-
申请号： US17355703申请日： 2021-06-23
-
公开(公告)号： US20210324090A1公开(公告)日： 2021-10-21
- 发明人: Javed Khan , Sivasubramanian Baskar , Rimas J. Orentas , Dimiter S. Dimitrov , Zhongyu Zhu , Tai Chi Cheuk
- 申请人： The U.S.A., as represented by the Secretary, Department of Health and Human Services
- 申请人地址： US MD Bethesda
- 专利权人： The U.S.A., as represented by the Secretary, Department of Health and Human Services
- 当前专利权人： The U.S.A., as represented by the Secretary, Department of Health and Human Services
- 当前专利权人地址： US MD Bethesda
- 主分类号： C07K16/28
- IPC分类号： C07K16/28 ; A61K47/68 ; A61K47/69 ; A61P35/00 ; A61K39/395
摘要：
Monoclonal antibodies selected from immunized mice, immunized rabbits and a human scFv library that specifically bind fibroblast growth factor receptor 4 (FGFR4) are described. Chimeric antigen receptors, antibody-drug conjugates, immunoconjugates, bispecific antibodies and immunoliposomes comprising the disclosed FGFR4-specific antibodies are also described. The antibody compositions can be used to diagnose or treat a FGFR4-positive cancer, such as rhabdomyosarcoma, lung cancer, liver cancer, breast cancer, pancreatic cancer or prostate cancer.
信息查询
